Holen Sie sich die Stockscreener-App
52.57
1.18%
-0.9952
Schlusskurs vom Vortag:
$53.57
Offen:
$53.03
24-Stunden-Volumen:
303.79K
Relative Volume:
0.13
Marktkapitalisierung:
$10.10B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
19.54
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
+0.51%
1M Leistung:
-4.49%
6M Leistung:
-14.65%
1J Leistung:
-20.51%
1-Tages-Spanne:
$52.60
$54.25
1-Wochen-Bereich:
$51.00
$56.80
52-Wochen-Spanne:
$51.00
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
52.60 | 10.29B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.50 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.12 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
828.79 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.35 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Bernstein lowers BioMarin stock price target to $88 on growth concerns - Investing.com Nigeria
Eleva Capital SAS Invests $1.29 Million in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin Pharmaceutical Inc. (BM8) stock cheap by valuation metricsDollar Strength & Weekly Stock Performance Updates - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock hit analyst forecastsQuarterly Profit Summary & Low Risk Entry Point Tips - newser.com
Keybank National Association OH Sells 19,707 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call - TradingView
Can BioMarin Pharmaceutical Inc. stock hit analyst price targets2025 Buyback Activity & Consistent Profit Alerts - newser.com
How to manage a losing position in BioMarin Pharmaceutical Inc.Day Trade & Fast Momentum Entry Tips - newser.com
Exit strategy if you’re trapped in BioMarin Pharmaceutical Inc.July 2025 Fed Impact & Real-Time Market Trend Scan - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetMarket Growth Summary & Free Fast Gain Swing Trade Alerts - newser.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
What is William Blair's Estimate for BMRN Q4 Earnings? - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 14,700 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Can BioMarin Pharmaceutical Inc. (BM8) stock reach $200 price targetOptions Play & Weekly Return Optimization Plans - newser.com
Why BioMarin Pharmaceutical Inc. stock is in analyst buy zoneWeekly Trend Report & Safe Capital Growth Stock Tips - newser.com
Why BioMarin Pharmaceutical Inc. stock is seen as undervaluedJobs Report & Free Technical Pattern Based Buy Signals - newser.com
Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN) - MSN
BioMarin Pharmaceutical (BMRN): Evaluating Valuation as Shares Recover 3% After Prolonged Downtrend - Sahm
How to monitor BioMarin Pharmaceutical Inc. with trend dashboards2025 Valuation Update & High Yield Stock Recommendations - newser.com
10 Best Beaten Down Growth Stocks to Buy According to Analysts - Insider Monkey
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Cantor Fitzgerald Has Negative View of BMRN FY2025 Earnings - MarketBeat
How currency fluctuations impact BioMarin Pharmaceutical Inc. stock2025 Technical Overview & Safe Swing Trade Setups - newser.com
How to read the order book for BioMarin Pharmaceutical Inc.Market Activity Report & Daily Profit Focused Stock Screening - newser.com
Sentiment analysis tools applied to BioMarin Pharmaceutical Inc.Global Markets & AI Enhanced Trading Alerts - newser.com
BioMarin Pharmaceutical (BMRN) Announces Financial Results for Q3 2025 - Insider Monkey
13 Stocks to Buy with Exponential Growth Heading into 2026 - Insider Monkey
BioMarin Pharmaceutical Inc. Just Missed Earnings With A Surprise LossHere Are Analysts Latest Forecasts - Yahoo Finance
Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts - simplywall.st
Biomarin Pharmaceutical stock hits 52-week low at 51.52 USD By Investing.com - Investing.com South Africa
After a futile battle, Biomarin will sell the bleeding disorder drug Roctavian - medwatch.com
Biomarin Pharmaceutical stock hits 52-week low at 51.52 USD - Investing.com
Cantor Fitzgerald Issues Negative Forecast for BMRN Earnings - MarketBeat
BioMarin Pharma plans to divest struggling gene therapy - MSN
Results: BioMarin Pharmaceutical Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts - 富途牛牛
BioMarin Pharmaceutical (NASDAQ:BMRN) Earns Outperform Rating from Wedbush - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Cut to $70.00 by Analysts at Wells Fargo & Company - MarketBeat
Stifel Nicolaus Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $73.00 - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $80.00 at Barclays - MarketBeat
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):